Objective-To estimate the lifetime risk of colorectal cancer in the general population and in first degree relatives of patients with sporadic colorectal cancer or adenoma. Main outcomes measures-The cumulative risk of colorectal cancer (0-74) in the general population combined with the relative risk of colorectal cancer and the prevalence of diVerent groups of subjects with family history of colorectal tumour allows the calculation of cumulative risks in these groups. Results-The lifetime risk of colorectal cancer was 1 in 23 in men and 1 in 40 in women. In males, 0.5% in the 55-59 age group and 4.5% in the 70-74 age group will develop a colorectal cancer. The corresponding values in females were 0.4% and 2.5%. The cumulative risk at age 74 varied between 7.7% (one family member affected) and 25.6% (two aVected) in males, and 4.3% and 14.3% respectively in females. The risk in the 40-44 year age group for individuals with one first degree relative aVected before 45 years of age was 0.5%, similar to that of those aged 45-49 with one first degree relative aVected with a colorectal cancer or a large adenoma (> 1 cm). Conclusions-These results suggest that screening in the general population should start at 50 or 55. The lifetime risk is high enough (over 10%) among individuals with one aVected first degree relative before age 45, or with at least two aVected first degree relatives, to warrant colonoscopic screening. The data provide a basis for recommendations that relatives of these patients should enter screening programmes at age 40 to 44. (J Med Screen 2000;7:136-140) 
Colorectal cancer (CRC) is the second most frequent cancer in developed countries.
1 For both sexes, it ranks first in France along with breast cancer as 33 400 new cases are reported annually. 2 Despite advances in diagnostic techniques and treatment, the prognosis of colorectal cancer in population based statistics remains poor. In the EUROCARE study, the five year crude survival rate was estimated to be 37% for colon cancer, and 35% for rectal cancer. 3 Screening represents one way to improve these statistics. Its aim is to prevent death from colorectal cancer by detecting and treating curable cancers and to prevent cancer by removing precancerous lesions-for example, large adenomas. The risk of colorectal cancer is one important determinant for whether and how to screen. Precise quantification of colorectal cancer risk would allow clinicians, policy makers, and patients to weigh more eVectively the risks and potential benefits of alternative management strategies. In an asymptomatic population, colorectal cancer risk is mainly dependent on age and family history of colorectal tumour. The aim of this study was to estimate the lifetime risk of colorectal cancer in the general population and in first degree relatives of patients with sporadic colorectal cancer or adenoma.
Methods

LIFETIME RISK OF COLORECTAL CANCER IN THE GENERAL POPULATION
The cancer incidence data were extracted from the population based digestive tract cancer registry which covers the resident population of the Côte d'Or area (Burgundy, France) (507 000 inhabitants in 1998). Information is obtained regularly from pathology laboratories, university hospitals, local hospitals, private physicians, surgeons, gastroenterologists, oncologists, and general practitioners. No cases were registered through death certificates alone but they were used to identify missing cases. Completeness and quality of the collected data is certified every four years by an audit of the National Institute for Health and Medical Research (INSERM) and of the Ministry of Health. Specific site was registered according to the ninth revision of the International Classification of Diseases. 4 Mid-year estimates by sex and age of the population were calculated annually cohortwise by linear interpolation from the data of the three national censuses (1975, 1982, 1990 ) and by extrapolation thereafter.
CUMULATIVE RISK
The cumulative risk of colorectal cancer by sex and age was calculated. It is the risk for an individual of developing a disease during a certain age period, if no other causes of death are in operation. It is the sum over each year of age of the age specific incidence rates, taken from birth to age 74. In practice, it is five times the sum of the age specific incidence rates calculated by five year age groups. It is expressed as a percentage and can be interpreted either as a directly age standardised rate with the same population size in each group, or as a cumulative rate. The cumulative risk of colorectal cancer in the general population (R) can be combined with the relative risk of colorectal cancer for subjects with family history of colorectal cancer or of adenoma, obtained from analytical studies (r) and with the prevalence of these subjects (P) so as to obtain measure of risk for particular groups (R 1 ) 5 :
Both the relative risk in first degree relatives of patients with sporadic colorectal tumour or adenoma and the corresponding prevalence of these groups were obtained from several sources of data. In a case control study in the Burgundy area, we investigated the relation between family history of colorectal cancer among first degree relatives of both colorectal cancers and adenomas. 6 Patients eligible for the study were residents of the Côte d'Or area, aged 30 to 79. Between April 1985 and April 1990, 171 patients with a histologically confirmed colon or rectal carcinoma were recruited from all public and private gastroenterologists of the Côte d'Or area, as were 208 patients with at least one adenoma 10 mm or more in diameter, 154 patients with only small adenomas, 426 polyp free controls, and 309 general population controls. All subjects were interviewed at home about their personal and familial medical history as well as their diet. The odds ratio for family history of colorectal cancer were 2.1 (95% CI: 1.1-3.7) for colorectal cancer, 2.1 (1.3-3.4) for large adenomas (> 1 cm) and 1.2 (0.7-2.2) for small adenomas. Most other available data are limited to family history and colorectal cancer risk. Odds ratios, similar to those found in our study, were reported in five other case control studies [7] [8] [9] [10] [11] and two cohort studies. 12 13 There are few data available on cancer risk in first degree relatives of patients with adenomas, 6 14 in particular according to adenoma size.
Our data do not allow us to quantify colorectal cancer risk in first degree relatives of patients under 45 years or in those with two or more first degree relatives, the number of cases being too small. To quantify this risk, we used the data from St John et al. 9 In this study, the odds ratio was 3.7 (1.5-9.1) for subjects with one aVected first degree relative diagnosed before age 45 and it was 1.8 (1.2-2.9) both in the 45-54 and over 55 age groups. These data were close to those reported in our study, which mainly include cases over 45. The odds ratio was 5.7 (1.7-19.3) for subjects with at least two aVected relatives.
Our study also indicated that in a population sample, a family history of colorectal cancer was seen in 8.1% of the population. Similar findings (8.2%) were reported in a centre for periodic health examination in the south of France, 15 which also indicated that the prevalence of subjects with two aVected first degree relatives was 0.1%. The prevalence of large adenomas was obtained from a necropsy study performed in Burgundy and was 12.3%. 16 
Results
LIFETIME RISK OF COLORECTAL CANCER IN THE GENERAL POPULATION
During the 1976-95 period, 4749 colorectal cancers were recorded among the Côte d'Or residents; 52.2% of all digestive tract cancers. The age standardised incidence rates were 36.9 per 100 000 in men and 24.6 per 100 000 in women, and the corresponding cumulative rates (0-74 years) were 4.4% and 2.5%. The mean age at diagnosis was slightly lower in men than in women (mean (SD) 69.5 (11.7) v 72.6 (12.8), p < 0.001). Figure 1 shows age specific incidence rates for colorectal cancer in men and women. Colorectal cancer was rare before the age of 50: 6.3% of the cases in men and 6.0% of the cases in women. Incidence rates were relatively similar in both sexes before age 55. Then, they increased more rapidly in men than in women. Between age 55 and 74, the sex ratio ranged from 1.5 to 2.1. Age specific incidence rates doubled at each decade in men, whereas the increase was slightly lower in women. The proportion of males and females aged 35 years and over who will develop a colorectal cancer in each five year age group is given in table 1. In the 55-59 age group, it was 0.5% in males and 0.4% in females. The corresponding values for those aged 70-74 were respectively 4.5% and 2.5%. Table 2 shows the relative risk of colorectal cancer in first degree relatives of aVected individuals according to the age at which colorectal cancer occurred in the index case, and according to the number of aVected family members. It also shows the prevalence of these groups in the general population and the cumulative risk at age 74. In men, the cumulative risk varied between 7.7% (one aVected family member after age 45) and 25.6% (two aVected first degree relatives). The corresponding values in women were respectively 4.3% and 14.3%. Risk of colorectal cancer by age group and sex in first degree relatives of patients with colorectal cancer or large adenomas is given in table 3. It became relevant-about 0.5% in the 40-44 year age group-for individuals with one first degree relative aVected before 45 years old. A similar risk was seen in the 45-49 age group for individuals with one first degree relative aVected after 45 years of age, as well as in those with one first degree relative with large adenoma.
Discussion
Obtaining risk estimates for colorectal cancer in diVerent population subgroups would enable screening to be oVered to subjects based on their probability of developing colorectal cancer. The lifetime risk of colorectal cancer in France is 1 in 23 in males and 1 in 40 in females. The risk increases rapidly from age 50, becoming relevant (around 0.5%) only in the 55-59 age group. It has been shown in two population based studies that biennial screening with the Hemoccult test for subjects aged 50 to 74 could decrease colorectal cancer mortality between 14% and 18%. It was concluded from the results of these two studies that screening should start at age 50. 17 18 Although colorectal cancer risk is low in the 50-54 age group, the good compliance with faecal occult blood tests in this age group (over 55% in the Burgundy study 19 ), the low positivity rate (between 1% and 2%) according to the screening campaign, and the results of cost eVectiveness analysis 20 21 makes screening with faecal occult blood tests starting at age 50 an acceptable compromise. If sigmoidoscopic or colonoscopic screening is to be used, it should be avoided before 55 because of the greater aggressiveness of the techniques, the possible danger and cost. Screeners must be informed of the potential complications of endoscopy. 22 We will know more about the potential benefit and harm of sigmoidoscopy screening when the results of ongoing randomised studies in England and Italy are available. 23 24 Our data suggest that individuals with no colorectal risk factor must be considered at low risk until aged 50 or 55 according to the screening strategy used. These results strongly challenge recommendations to start screening at an earlier age. Screening is proposed until age 74. After that age, competitive causes of death become so frequent that intervention directed at reducing colorectal cancer risk is not warranted. By taking a careful family history, it is possible to identify people at increased risk of colorectal cancer. Familial adenomatosis coli and hereditary non-polyposis colorectal cancer are two well identified dominantly inheritant syndromes. Secondary prevention of colorectal cancer has already proved eVective, 25 but because of the rarity of those instances in the population, screening of these individuals will only marginally solve the problem of colorectal cancers. For instance during the period 1976-96, 23 colorectal cancers out of 5036 (0.5%) were diagnosed in individuals with familial adenomatosis coli. Family studies have shown that the risk of colorectal cancer in first degree relatives of patients with common colorectal cancer is, on average, twice as high as the risk in the general population. [7] [8] [9] The risk varies according to the age at diagnosis of the index case and the number of aVected first degree relatives. 9 12 26 The lifetime risk is high enough (over 10% among individuals with one aVected first degree relative before age 45 or with at least two aVected first degree relatives) to warrant colonoscopic screening even when taking into account adverse eVects of colonoscopy. 27 Our data provide a basis for recommendations that relatives of these patients should enter screening programmes at age 40 to 44, a decade earlier than average risk persons.
There are no clear conclusions regarding which screening strategy should be proposed for those with a lifetime risk between 5% and 10%. This group is relatively large, nearly 10% of the general population and 20% of all colorectal cancers. 6-8 12 The French consensus conference concluded that available data on compliance, risks, inconvenience, and cost, in particular for endoscopic screening, were not suYcient to propose a screening strategy. 28 Since a randomised controlled trial of screening in such a group is technically not feasible, decisions regarding screening can come from mathematical models that take into account colorectal cancer risk, and that are able to predict the outcomes of diVerent screening strategies as well as to provide cost eVective analysis. Our data suggest that screening in this group should start after age 50. Before that age, the risk is too low to expect that screening strategies will reduce risk further.
The risk of colorectal cancer is less clearly defined for those relatives of patients with large adenomas. Our data suggest that first degree relatives of patients with a large adenoma (> 1 cm) have an increased risk of colorectal cancer of the same order of magnitude as those with a first degree relative with colorectal cancer. In contrast, no significant excess risk was found in first degree relatives of patients with small adenomas. As for colorectal cancers, this increase in risk appears to be more pronounced if the index case is younger than 60 or 65. 6 Although our data need to be confirmed, we suggest that first degree relatives of index cases with colorectal cancer or large adenomas should be considered similarly. In these groups, screening should start at age 50, using a strategy which has yet to be defined. Because the risk associated with family history increases as the yet unaVected relative gets older, screening should be continued until age 74.
In conclusion, this study provides data on colorectal cancer risk taking into consideration both age and family history. In average risk populations, screening should start at age 50 or 55. The only eVective screening method at the moment is faecal occult blood testing. The eVectiveness of flexible sigmoidoscopy is currently being tested in randomised trials. The risk is high enough to advise a screening colonoscopy after age 40 for first degree relatives of patients with a colorectal cancer before the age of 45 or for those with at least two aVected first degree relatives. We do not have enough data to recommend which screening strategy to implement in the intermediate risk group (lifetime risk between 5% and 10%). However, our data do suggest that any screening strategy in this group should start at 50.
